Amplitude Energy (COPJF) Receives a Buy from Canaccord Genuity
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Bullen is a 2-star analyst with an average return of 0.8% and a 44.09% success rate. Bullen covers the Energy sector, focusing on stocks such as Amplitude Energy, Paladin Energy Ltd, and Bannerman Energy.
Amplitude Energy has an analyst consensus of Strong Buy, with a price target consensus of $0.20, a 46.25% upside from current levels. In a report released on July 17, Macquarie also maintained a Buy rating on the stock with a A$0.38 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Oppenheimer Reaffirms Their Buy Rating on Biogen (BIIB)
In a report released today, Jay Olson from Oppenheimer reiterated a Buy rating on Biogen, with a price target of $205.00. The company's shares closed today at $128.00. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Olson is a 3-star analyst with an average return of 2.8% and a 37.73% success rate. Olson covers the Healthcare sector, focusing on stocks such as Biogen, Ionis Pharmaceuticals, and Neurocrine. In addition to Oppenheimer, Biogen also received a Buy from TD Cowen's Phil Nadeau in a report issued today. However, on the same day, Needham maintained a Hold rating on Biogen (NASDAQ: BIIB). Based on Biogen's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.43 billion and a net profit of $240.5 million. In comparison, last year the company earned a revenue of $2.29 billion and had a net profit of $393.4 million Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is neutral on the stock. Earlier this month, Rachid Izzar, the Head of Global Product Strat of BIIB sold 2,223.00 shares for a total of $300,105.00.
Business Insider
an hour ago
- Business Insider
Roth MKM Remains a Buy on SM Energy (SM)
Roth MKM analyst Leo Mariani maintained a Buy rating on SM Energy yesterday and set a price target of $35.00. The company's shares closed today at $27.59. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Mariani covers the Energy sector, focusing on stocks such as EOG Resources, Diamondback, and EQT. According to TipRanks, Mariani has an average return of 28.5% and a 62.94% success rate on recommended stocks. In addition to Roth MKM, SM Energy also received a Buy from Siebert Williams Shank & Co's Gabriele Sorbara in a report issued on July 25. However, on July 23, Susquehanna maintained a Hold rating on SM Energy (NYSE: SM). The company has a one-year high of $47.69 and a one-year low of $19.67. Currently, SM Energy has an average volume of 2.29M. Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is neutral on the stock. Last month, Richard A. Jenkins, the SVP – Utah of SM sold 7,726.00 shares for a total of $220,113.74.
Yahoo
8 hours ago
- Yahoo
Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference
PALO ALTO, Calif., July 31, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Guardant Health's management is scheduled to participate in a fireside chat on Wednesday, August 13th at 9:30 a.m. ET. Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at: About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. View source version on Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Meaghan Smithpress@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
